Feb 7, 2018 Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Jan 22, 2018 Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARĪ± Agonist
Jan 8, 2018 Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms
Jan 2, 2018 Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARĪ± Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients
